Premium
Treating women with opioid use disorder during pregnancy in Appalachia: Initial neonatal outcomes following buprenorphine + naloxone exposure
Author(s) -
Nguyen Linda,
Lander Laura R.,
O'Grady Kevin E.,
Marshalek Patrick J.,
Schmidt Adrienne,
Kelly Audra K.,
Jones Hendrée E.
Publication year - 2018
Publication title -
the american journal on addictions
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.997
H-Index - 76
eISSN - 1521-0391
pISSN - 1055-0496
DOI - 10.1111/ajad.12687
Subject(s) - buprenorphine , medicine , opioid use disorder , (+) naloxone , pregnancy , obstetrics , opioid , methadone , gestational age , anesthesia , receptor , biology , genetics
Background and Objectives Rising concerns regarding diversion and misuse of mono‐buprenorphine for treatment of pregnant women with opioid use disorders have sparked interest in the use of buprenorphine + naloxone to reduce misuse and diversion rates. Examined the relationship of prenatal buprenorphine + naloxone exposure to neonatal outcomes. Methods This is a retrospective chart review of 26 mother infant dyads in comprehensive medication‐assisted treatment with buprenorphine + naloxone during pregnancy. Results All neonatal birth outcome parameters were within normal ranges, albeit on the lower side of normal for gestational age and birth weight. Only 19% of neonates required morphine pharmacology for NAS. Conclusions Use of buprenorphine + naloxone shows relative safety in pregnancy. Scientific Significance These findings can help better guide prescribing practices for pregnant patients at risk for misuse or diversion of buprenorphine. (Am J Addict 2018;27:92–96)